Do analysts rate HRTX or SIGA?

Heron Therapeutics currently has a consensus target price of $2.50, suggesting a potential upside of 470.26%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Heron Therapeutics 2 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.00 Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor HRTX or SIGA?

In the previous week, Heron Therapeutics and Heron Therapeutics both had 1 articles in the media. Heron Therapeutics' average media sentiment score of 0.85 beat Siga Technologies' score of 0.14 indicating that Heron Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heron Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Siga Technologies 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to HRTX or RNAC?

In the previous week, Cartesian Therapeutics had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for Cartesian Therapeutics and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.85 beat Cartesian Therapeutics' score of -0.65 indicating that Heron Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heron Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cartesian Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media favor HRTX or MGNX?

In the previous week, MacroGenics had 3 more articles in the media than Heron Therapeutics. MarketBeat recorded 4 mentions for MacroGenics and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.85 beat MacroGenics' score of 0.60 indicating that Heron Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Heron Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MacroGenics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Heron Therapeutics (HRTX) Competitors

$0.44 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.43 -0.01 (-1.69%)

As of 07/2/2026 06:28 PM Eastern

Compare

HRTX vs. SIGA, RNAC, ELDN, ORGO, and MGNX

Should you buy Heron Therapeutics stock or one of its competitors? MarketBeat compares Heron Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Heron Therapeutics include Siga Technologies (SIGA), Cartesian Therapeutics (RNAC), Eledon Pharmaceuticals (ELDN), Organogenesis (ORGO), and MacroGenics (MGNX). These companies are all part of the "pharmaceutical products" industry.

How does Heron Therapeutics compare to Siga Technologies?

Heron Therapeutics (NASDAQ:HRTX) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 55.4% of Siga Technologies shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Siga Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Heron Therapeutics and Heron Therapeutics both had 1 articles in the media. Heron Therapeutics' average media sentiment score of 0.85 beat Siga Technologies' score of 0.14 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Siga Technologies	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Siga Technologies has a net margin of 21.58% compared to Heron Therapeutics' net margin of -20.53%. Siga Technologies' return on equity of 10.60% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
Siga Technologies	21.58%	10.60%	8.94%

Heron Therapeutics currently has a consensus target price of $2.50, suggesting a potential upside of 470.26%. Given Heron Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Heron Therapeutics is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Heron Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the broader market. Comparatively, Siga Technologies has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

Siga Technologies has lower revenue, but higher earnings than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.54	-$20.19M	-$0.18	N/A
Siga Technologies	$94.57M	2.93	$23.28M	$0.27	14.30

Summary

Heron Therapeutics beats Siga Technologies on 8 of the 15 factors compared between the two stocks.

How does Heron Therapeutics compare to Cartesian Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Heron Therapeutics has a net margin of -20.53% compared to Cartesian Therapeutics' net margin of -8,550.65%. Cartesian Therapeutics' return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
Cartesian Therapeutics	-8,550.65%	N/A	-28.25%

Heron Therapeutics has higher revenue and earnings than Cartesian Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.54	-$20.19M	-$0.18	N/A
Cartesian Therapeutics	$1.78M	175.30	-$130.30M	-$5.90	N/A

Heron Therapeutics has a beta of 1.65, suggesting that its share price is 65% more volatile than the broader market. Comparatively, Cartesian Therapeutics has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market.

Heron Therapeutics presently has a consensus target price of $2.50, suggesting a potential upside of 470.26%. Cartesian Therapeutics has a consensus target price of $32.60, suggesting a potential upside of 207.84%. Given Heron Therapeutics' higher probable upside, equities analysts plainly believe Heron Therapeutics is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cartesian Therapeutics	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

In the previous week, Cartesian Therapeutics had 2 more articles in the media than Heron Therapeutics. MarketBeat recorded 3 mentions for Cartesian Therapeutics and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.85 beat Cartesian Therapeutics' score of -0.65 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cartesian Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 37.2% of Cartesian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Heron Therapeutics and Cartesian Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Heron Therapeutics compare to Eledon Pharmaceuticals?

Heron Therapeutics (NASDAQ:HRTX) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

Heron Therapeutics currently has a consensus target price of $2.50, indicating a potential upside of 470.26%. Eledon Pharmaceuticals has a consensus target price of $9.67, indicating a potential upside of 144.73%. Given Heron Therapeutics' higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Eledon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Eledon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Heron Therapeutics has higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.54	-$20.19M	-$0.18	N/A
Eledon Pharmaceuticals	N/A	N/A	-$45.62M	-$0.77	N/A

In the previous week, Heron Therapeutics had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 1 mentions for Heron Therapeutics and 0 mentions for Eledon Pharmaceuticals. Heron Therapeutics' average media sentiment score of 0.85 beat Eledon Pharmaceuticals' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Heron Therapeutics	Positive
Eledon Pharmaceuticals	Neutral

80.0% of Heron Therapeutics shares are held by institutional investors. Comparatively, 56.8% of Eledon Pharmaceuticals shares are held by institutional investors. 6.1% of Heron Therapeutics shares are held by company insiders. Comparatively, 9.6% of Eledon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Eledon Pharmaceuticals has a net margin of 0.00% compared to Heron Therapeutics' net margin of -20.53%. Eledon Pharmaceuticals' return on equity of -116.97% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
Eledon Pharmaceuticals	N/A	-116.97%	-41.91%

Heron Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, Eledon Pharmaceuticals has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Summary

Heron Therapeutics beats Eledon Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Heron Therapeutics compare to Organogenesis?

Heron Therapeutics (NASDAQ:HRTX) and Organogenesis (NASDAQ:ORGO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

Heron Therapeutics presently has a consensus price target of $2.50, suggesting a potential upside of 470.26%. Organogenesis has a consensus price target of $5.75, suggesting a potential upside of 143.64%. Given Heron Therapeutics' higher possible upside, equities analysts clearly believe Heron Therapeutics is more favorable than Organogenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Organogenesis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 49.6% of Organogenesis shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 18.8% of Organogenesis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Heron Therapeutics had 1 more articles in the media than Organogenesis. MarketBeat recorded 1 mentions for Heron Therapeutics and 0 mentions for Organogenesis. Heron Therapeutics' average media sentiment score of 0.85 beat Organogenesis' score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Heron Therapeutics	Positive
Organogenesis	Neutral

Organogenesis has a net margin of -0.84% compared to Heron Therapeutics' net margin of -20.53%. Organogenesis' return on equity of 9.63% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
Organogenesis	-0.84%	9.63%	4.76%

Organogenesis has higher revenue and earnings than Heron Therapeutics. Organogenesis is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.54	-$20.19M	-$0.18	N/A
Organogenesis	$512.59M	0.59	$37.03M	-$0.19	N/A

Heron Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, Organogenesis has a beta of 1.33, indicating that its share price is 33% more volatile than the broader market.

Summary

Heron Therapeutics beats Organogenesis on 8 of the 15 factors compared between the two stocks.

How does Heron Therapeutics compare to MacroGenics?

Heron Therapeutics (NASDAQ:HRTX) and MacroGenics (NASDAQ:MGNX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Heron Therapeutics has a beta of 1.65, indicating that its share price is 65% more volatile than the broader market. Comparatively, MacroGenics has a beta of 1.18, indicating that its share price is 18% more volatile than the broader market.

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 96.9% of MacroGenics shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 13.6% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Heron Therapeutics has higher revenue and earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.54	-$20.19M	-$0.18	N/A
MacroGenics	$149.50M	2.00	-$74.62M	-$1.10	N/A

In the previous week, MacroGenics had 3 more articles in the media than Heron Therapeutics. MarketBeat recorded 4 mentions for MacroGenics and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 0.85 beat MacroGenics' score of 0.60 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heron Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MacroGenics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Heron Therapeutics has a net margin of -20.53% compared to MacroGenics' net margin of -44.79%. MacroGenics' return on equity of -147.80% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
MacroGenics	-44.79%	-147.80%	-28.40%

Heron Therapeutics presently has a consensus price target of $2.50, indicating a potential upside of 470.26%. MacroGenics has a consensus price target of $5.50, indicating a potential upside of 16.77%. Given Heron Therapeutics' higher probable upside, analysts clearly believe Heron Therapeutics is more favorable than MacroGenics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
MacroGenics	1 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.29

Summary

Heron Therapeutics beats MacroGenics on 9 of the 16 factors compared between the two stocks.

Get Heron Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HRTX vs. The Competition

Export

Metric	Heron Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$82.98M	$3.10B	$7.16B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.52%
P/E Ratio	-2.44	20.06	28.02	24.70
Price / Sales	0.54	360.33	540.37	99.46
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	6.26	4.32	10.96	6.46
Net Income	-$20.19M	$64.45M	$3.57B	$337.01M
7 Day Performance	1.95%	2.97%	2.12%	1.69%
1 Month Performance	2.57%	6.83%	5.25%	3.81%
1 Year Performance	-79.75%	29.07%	33.29%	23.90%

Heron Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HRTX Heron Therapeutics	2.4767 of 5 stars	$0.44 flat	$2.50 +470.3%	-79.8%	$82.98M	$154.90M	N/A	300
SIGA Siga Technologies	0.915 of 5 stars	$4.39 +1.3%	N/A	-42.7%	$314.49M	$94.57M	16.24	40	Analyst Downgrade Gap Down
RNAC Cartesian Therapeutics	3.8318 of 5 stars	$10.67 +7.3%	$32.60 +205.4%	-5.2%	$313.68M	$1.78M	N/A	64	News Coverage Analyst Downgrade Gap Down
ELDN Eledon Pharmaceuticals	1.4091 of 5 stars	$3.99 +4.7%	$9.67 +142.4%	+31.4%	$312.77M	N/A	N/A	10
ORGO Organogenesis	1.8027 of 5 stars	$2.40 -1.4%	$5.75 +140.1%	-45.7%	$308.18M	$512.59M	N/A	950	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HRTX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Heron Therapeutics (HRTX) Competitors

HRTX vs. SIGA, RNAC, ELDN, ORGO, and MGNX

How does Heron Therapeutics compare to Siga Technologies?

Summary

How does Heron Therapeutics compare to Cartesian Therapeutics?

Summary

How does Heron Therapeutics compare to Eledon Pharmaceuticals?

Summary

How does Heron Therapeutics compare to Organogenesis?

Summary

How does Heron Therapeutics compare to MacroGenics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX vs. The Competition

Heron Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Heron Therapeutics (HRTX) Competitors

HRTX vs. SIGA, RNAC, ELDN, ORGO, and MGNX

How does Heron Therapeutics compare to Siga Technologies?

Do insiders and institutionals have more ownership in HRTX or SIGA?

Does the media favor HRTX or SIGA?

Is HRTX or SIGA more profitable?

Do analysts rate HRTX or SIGA?

Which has more risk & volatility, HRTX or SIGA?

Which has higher earnings and valuation, HRTX or SIGA?

Summary

How does Heron Therapeutics compare to Cartesian Therapeutics?

Is HRTX or RNAC more profitable?

Which has better earnings & valuation, HRTX or RNAC?

Which has more risk & volatility, HRTX or RNAC?

Do analysts prefer HRTX or RNAC?

Does the media refer more to HRTX or RNAC?

Do institutionals and insiders have more ownership in HRTX or RNAC?

Summary

How does Heron Therapeutics compare to Eledon Pharmaceuticals?

Do analysts rate HRTX or ELDN?

Which has higher earnings and valuation, HRTX or ELDN?

Does the media favor HRTX or ELDN?

Do institutionals and insiders believe in HRTX or ELDN?

Is HRTX or ELDN more profitable?

Which has more volatility and risk, HRTX or ELDN?

Summary

How does Heron Therapeutics compare to Organogenesis?

Do analysts recommend HRTX or ORGO?

Do insiders and institutionals have more ownership in HRTX or ORGO?

Does the media favor HRTX or ORGO?

Is HRTX or ORGO more profitable?

Which has better valuation & earnings, HRTX or ORGO?

Which has more volatility and risk, HRTX or ORGO?

Summary

How does Heron Therapeutics compare to MacroGenics?

Which has more volatility and risk, HRTX or MGNX?

Do institutionals and insiders have more ownership in HRTX or MGNX?

Which has stronger earnings and valuation, HRTX or MGNX?

Does the media favor HRTX or MGNX?

Is HRTX or MGNX more profitable?

Do analysts rate HRTX or MGNX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX vs. The Competition

Heron Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools